title: [Irritable bowel disease: recent developments].
authors.affiliation: Klinik für Innere Medizin und Gastroenterologie, Katholische Kliniken Ruhrhalbinsel, Essen. s.boehm@kkrh.de
authors.forename: S K
authors.initials: SK
authors.lastname: Böhm
authors.forename: W
authors.initials: W
authors.lastname: Kruis
mesh_terms: D000465:Algorithms; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D001572:Benzofurans / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D050528:Diet, Carbohydrate-Restricted; D019317:Evidence-Based Medicine; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000145:classification / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012294:Rifamycins / Q000009:adverse effects / Q000627:therapeutic use; D000078262:Rifaximin
chemical_list: D000890:Anti-Infective Agents; D001572:Benzofurans; D005765:Gastrointestinal Agents; D012294:Rifamycins; C406662:prucalopride; D000078262:Rifaximin